Whole-tumor-cell cancers as vaccines can deliver a wide spectrum of tumor antigens and successfully activate anti-tumor responses. Gene-modified cancer cells are now considered to be the best way to achieve immunotherapy for a variety of cancers including hematological tumors and solid tumors. Cancer cells genetically modified to secrete designer cytokines can increase their immunogenicity and generate systemic antitumor immunity in vivo. Currently, many clinical studies are investigating the safety and efficacy of autologous and allogeneic whole-cell-based cancer vaccines. As a reliable and trusted contract research organization, Creative Biolabs offers customized services to generate IL2-overexpressed cancer cells, at a lower cost and in a shorter time. We can help you design a custom solution that fits your unique requirement.

IL-6 Functions in T Cell Activation

Interleukein-6 (IL-6) is a pleiotropic cytokine that acts as both a pro-inflammatory and anti-inflammatory mediator that plays an important role in the proliferation and differentiation of cells in humans. IL-6 was originally known as B cell stimulating factor-2, which induces the production of antibodies by activated B cells. IL-6 also has been defined as a T cell activation factor and shown to induce T cell proliferation and survival. The impact of IL-6 on T cell subsets includes:

• IL-6 alone induces the differentiation of CD8+ T cells into IL-21–producing cells.
• IL-6 induces the generation of Th17 cells from naïve T cells together with TGF-β.
• IL-6 enhances Th2 differentiation through an autofeedback by up-regulating IL-4 production.
• IL-6 promotes CD4 T follicular helper cell differentiation and induces IL-21 production by naïve CD4 T cells.
• IL-6 inhibits Th1 and regulatory T cell (Treg) differentiation.

Fig.1 The functions of IL-6 in chronic inflammation and inflammation-associated cancer. (Neurath & Finotto, 2011)

Studies Performed with IL-6 Overexpressing Tumor Cells

• A study showed IL-6 gene-transfected melanoma cell vaccine could achieve a potent antitumor effect via efficient activation of specific and non-specific antitumor immune responses.
• Vaccination with hyper-IL6-modified cells resulted in the generation of antigen-specific CD8+, and CD4+ T lymphocytes and the elimination of cancer cells in an orthotopic murine prostate cancer model.

Engineering Cancer Cells with IIL-6 Overexpression Service

Creative Biolabs can help researchers work with novel cancer immunotherapy projects. With our well-established platform, our experts can produce any IL6-gene-modified cancer cells for your basic research and clinical transformation. In addition, we also have developed a series of functional assays for evaluating antigen-specific T activation, cancer cell killing, etc. Our customer service accompanies you at each single step. Because each project is different, we can customize our offering to meet your specific project needs.

Our cancer cell engineering services cover a range of different cell lines. The following lists the available cancer cell types:

• Service Details

Key Features

• One-stop-solution
• Fast turnaround time and end-to-end services
• Extensive experience and proprietary technologies
• Highest confidentiality and quality standards

Creative Biolabs provides high-quality services to engineer cancer cell lines of your interest with a fast turnaround time. Each project is customized for the desired deliverables by working directly with our team of highly trained scientists. If you are interested in our services, please don’t hesitate to contact us.

Reference

1. Neurath, MF.; Finotto, S. IL-6 signaling in autoimmunity, chronic inflammation, and inflammation-associated cancer. Cytokine & growth factor reviews. 2011, 22(2):83-9.

For Research Use Only | Not For Clinical Use